Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clostridium difficile | 11 | 2016 | 22 | 2.990 |
Why?
|
| Clostridium Infections | 7 | 2019 | 13 | 2.330 |
Why?
|
| Enterocolitis, Pseudomembranous | 6 | 2015 | 13 | 1.850 |
Why?
|
| Cross Infection | 7 | 2019 | 24 | 1.530 |
Why?
|
| Vaccination | 9 | 2026 | 726 | 1.370 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2026 | 37 | 1.310 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2026 | 157 | 1.230 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2026 | 9 | 1.120 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2025 | 26 | 1.110 |
Why?
|
| Young Adult | 20 | 2026 | 2538 | 0.980 |
Why?
|
| Humans | 51 | 2026 | 17622 | 0.940 |
Why?
|
| Adult | 31 | 2026 | 7621 | 0.930 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 25 | 0.870 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2025 | 368 | 0.830 |
Why?
|
| Male | 33 | 2026 | 10014 | 0.780 |
Why?
|
| Analgesics, Opioid | 3 | 2021 | 258 | 0.780 |
Why?
|
| Female | 35 | 2026 | 12715 | 0.760 |
Why?
|
| Health Personnel | 5 | 2022 | 135 | 0.750 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2025 | 380 | 0.720 |
Why?
|
| Accelerometry | 1 | 2021 | 57 | 0.660 |
Why?
|
| Middle Aged | 25 | 2026 | 7954 | 0.640 |
Why?
|
| Adolescent | 22 | 2026 | 3625 | 0.630 |
Why?
|
| Incidence | 10 | 2025 | 1278 | 0.590 |
Why?
|
| Pericarditis | 2 | 2018 | 11 | 0.590 |
Why?
|
| Infant | 10 | 2026 | 1228 | 0.570 |
Why?
|
| Myocarditis | 2 | 2018 | 14 | 0.550 |
Why?
|
| Health Services | 2 | 2016 | 110 | 0.550 |
Why?
|
| Population Surveillance | 3 | 2014 | 248 | 0.550 |
Why?
|
| Viral Vaccines | 1 | 2018 | 12 | 0.540 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 14 | 0.540 |
Why?
|
| Vaccines, Attenuated | 1 | 2018 | 44 | 0.540 |
Why?
|
| Health Services for the Aged | 1 | 2018 | 14 | 0.540 |
Why?
|
| Aged | 18 | 2026 | 6223 | 0.540 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 185 | 0.540 |
Why?
|
| Oregon | 7 | 2026 | 172 | 0.530 |
Why?
|
| Family Characteristics | 3 | 2026 | 70 | 0.530 |
Why?
|
| Deprescriptions | 1 | 2018 | 11 | 0.530 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 35 | 0.530 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 193 | 0.510 |
Why?
|
| Ambulatory Care | 2 | 2015 | 228 | 0.480 |
Why?
|
| Patient-Centered Care | 2 | 2017 | 190 | 0.480 |
Why?
|
| Public Health Surveillance | 2 | 2022 | 42 | 0.480 |
Why?
|
| Washington | 6 | 2026 | 388 | 0.470 |
Why?
|
| Risk Management | 1 | 2016 | 4 | 0.470 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 14 | 0.470 |
Why?
|
| Exercise | 1 | 2021 | 538 | 0.470 |
Why?
|
| Medication Adherence | 2 | 2017 | 232 | 0.460 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 269 | 0.450 |
Why?
|
| Risk | 2 | 2022 | 492 | 0.440 |
Why?
|
| Decision Making | 2 | 2017 | 177 | 0.410 |
Why?
|
| Viral Load | 3 | 2026 | 110 | 0.410 |
Why?
|
| Retrospective Studies | 9 | 2022 | 2502 | 0.390 |
Why?
|
| Influenza, Human | 3 | 2026 | 294 | 0.380 |
Why?
|
| Surveys and Questionnaires | 5 | 2025 | 1296 | 0.380 |
Why?
|
| Community-Acquired Infections | 2 | 2019 | 20 | 0.380 |
Why?
|
| Prospective Studies | 11 | 2026 | 1251 | 0.370 |
Why?
|
| Child | 12 | 2026 | 2485 | 0.370 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 64 | 0.360 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 204 | 0.360 |
Why?
|
| Child, Preschool | 8 | 2026 | 1455 | 0.360 |
Why?
|
| Risk Factors | 9 | 2026 | 3291 | 0.360 |
Why?
|
| Health Expenditures | 1 | 2012 | 72 | 0.350 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 383 | 0.340 |
Why?
|
| Northwestern United States | 4 | 2021 | 53 | 0.340 |
Why?
|
| Antibodies, Viral | 3 | 2026 | 73 | 0.330 |
Why?
|
| Aged, 80 and over | 6 | 2022 | 1976 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 4 | 2016 | 152 | 0.290 |
Why?
|
| Colorado | 3 | 2014 | 170 | 0.280 |
Why?
|
| Personnel, Hospital | 1 | 2008 | 9 | 0.270 |
Why?
|
| Anti-Infective Agents | 3 | 2016 | 13 | 0.270 |
Why?
|
| Hospitals, Rural | 1 | 2007 | 6 | 0.270 |
Why?
|
| Pregnancy | 4 | 2026 | 1565 | 0.270 |
Why?
|
| Cohort Studies | 6 | 2026 | 2502 | 0.260 |
Why?
|
| Hospitalization | 5 | 2022 | 831 | 0.260 |
Why?
|
| United States | 10 | 2026 | 3922 | 0.250 |
Why?
|
| Enterovirus Infections | 1 | 2026 | 3 | 0.250 |
Why?
|
| Enterovirus D, Human | 1 | 2026 | 3 | 0.250 |
Why?
|
| Qualitative Research | 2 | 2018 | 290 | 0.250 |
Why?
|
| Genome, Viral | 1 | 2026 | 7 | 0.240 |
Why?
|
| Genetic Variation | 1 | 2026 | 82 | 0.230 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2026 | 98 | 0.230 |
Why?
|
| Intention | 1 | 2025 | 28 | 0.230 |
Why?
|
| Metapneumovirus | 1 | 2025 | 7 | 0.220 |
Why?
|
| Paramyxoviridae Infections | 1 | 2025 | 8 | 0.220 |
Why?
|
| Parents | 2 | 2025 | 301 | 0.220 |
Why?
|
| Emergency Responders | 2 | 2021 | 4 | 0.220 |
Why?
|
| Influenza Vaccines | 1 | 2008 | 301 | 0.210 |
Why?
|
| Pharmacists | 2 | 2021 | 50 | 0.200 |
Why?
|
| Case-Control Studies | 5 | 2019 | 1107 | 0.200 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 702 | 0.190 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 23 | 0.180 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2014 | 213 | 0.180 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 46 | 0.180 |
Why?
|
| Vancomycin | 2 | 2012 | 4 | 0.180 |
Why?
|
| Child Abuse, Sexual | 1 | 2021 | 13 | 0.180 |
Why?
|
| Angioedema | 1 | 2021 | 6 | 0.180 |
Why?
|
| Occupations | 1 | 2021 | 15 | 0.170 |
Why?
|
| Pharmacy | 1 | 2021 | 12 | 0.170 |
Why?
|
| Vital Signs | 1 | 2021 | 12 | 0.170 |
Why?
|
| Occupational Diseases | 1 | 2021 | 38 | 0.170 |
Why?
|
| Antibodies, Neutralizing | 3 | 2026 | 13 | 0.170 |
Why?
|
| Time Factors | 4 | 2022 | 1038 | 0.160 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 226 | 0.160 |
Why?
|
| Mental Health | 1 | 2021 | 163 | 0.160 |
Why?
|
| Physicians | 1 | 2021 | 120 | 0.160 |
Why?
|
| Odds Ratio | 2 | 2012 | 631 | 0.160 |
Why?
|
| Chronic Disease | 3 | 2019 | 398 | 0.160 |
Why?
|
| Logistic Models | 3 | 2015 | 866 | 0.150 |
Why?
|
| Patient Participation | 1 | 2021 | 124 | 0.150 |
Why?
|
| Communication | 1 | 2021 | 181 | 0.150 |
Why?
|
| Veterans Health | 1 | 2019 | 16 | 0.150 |
Why?
|
| Railroads | 1 | 2019 | 3 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 129 | 0.140 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 363 | 0.140 |
Why?
|
| Syncope | 1 | 2018 | 11 | 0.140 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2018 | 10 | 0.140 |
Why?
|
| Acute Pain | 1 | 2018 | 11 | 0.140 |
Why?
|
| Health Surveys | 1 | 2019 | 242 | 0.140 |
Why?
|
| Environment Design | 1 | 2019 | 67 | 0.140 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2018 | 17 | 0.140 |
Why?
|
| Length of Stay | 2 | 2010 | 182 | 0.140 |
Why?
|
| Infection Control | 2 | 2007 | 8 | 0.130 |
Why?
|
| Life Change Events | 1 | 2018 | 31 | 0.130 |
Why?
|
| Adolescent Health Services | 1 | 2018 | 40 | 0.130 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2016 | 4 | 0.130 |
Why?
|
| Child Health Services | 1 | 2018 | 107 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 193 | 0.120 |
Why?
|
| Electronic Health Records | 3 | 2019 | 719 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2022 | 1093 | 0.120 |
Why?
|
| Recurrence | 1 | 2016 | 166 | 0.120 |
Why?
|
| Mental Health Services | 1 | 2018 | 155 | 0.120 |
Why?
|
| Trimethoprim | 1 | 2015 | 4 | 0.120 |
Why?
|
| Heart Failure | 1 | 2021 | 414 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2015 | 14 | 0.120 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2015 | 15 | 0.120 |
Why?
|
| Patient Admission | 1 | 2016 | 69 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 68 | 0.120 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 43 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 168 | 0.110 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2015 | 3 | 0.110 |
Why?
|
| Vaccines | 1 | 2018 | 225 | 0.110 |
Why?
|
| Algorithms | 1 | 2016 | 227 | 0.110 |
Why?
|
| Self Administration | 1 | 2014 | 8 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2016 | 171 | 0.110 |
Why?
|
| Electronic Mail | 1 | 2014 | 51 | 0.110 |
Why?
|
| Quality of Life | 1 | 2018 | 505 | 0.100 |
Why?
|
| Inpatients | 1 | 2014 | 78 | 0.100 |
Why?
|
| Outpatients | 1 | 2014 | 103 | 0.100 |
Why?
|
| Telephone | 1 | 2014 | 159 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2015 | 304 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2015 | 205 | 0.100 |
Why?
|
| Prognosis | 1 | 2014 | 609 | 0.100 |
Why?
|
| Comorbidity | 1 | 2014 | 552 | 0.100 |
Why?
|
| Metronidazole | 1 | 2012 | 4 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2012 | 228 | 0.090 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 40 | 0.090 |
Why?
|
| Iowa | 2 | 2007 | 38 | 0.080 |
Why?
|
| Delivery, Obstetric | 1 | 2010 | 18 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 143 | 0.080 |
Why?
|
| California | 1 | 2016 | 2433 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2026 | 842 | 0.070 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2008 | 2 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2008 | 14 | 0.070 |
Why?
|
| Administrative Personnel | 1 | 2008 | 5 | 0.070 |
Why?
|
| Infection Control Practitioners | 1 | 2007 | 1 | 0.070 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 37 | 0.070 |
Why?
|
| Immunization Programs | 1 | 2008 | 64 | 0.070 |
Why?
|
| Borrelia burgdorferi Group | 2 | 1998 | 2 | 0.070 |
Why?
|
| Lyme Disease | 2 | 1998 | 4 | 0.070 |
Why?
|
| DNA, Bacterial | 2 | 1998 | 10 | 0.070 |
Why?
|
| Phylogeny | 1 | 2026 | 19 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2018 | 107 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 35 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2026 | 162 | 0.050 |
Why?
|
| Premature Birth | 1 | 2026 | 136 | 0.050 |
Why?
|
| Primary Health Care | 2 | 2021 | 729 | 0.050 |
Why?
|
| Arthritis, Infectious | 1 | 1982 | 1 | 0.050 |
Why?
|
| Yersinia Infections | 1 | 1982 | 1 | 0.050 |
Why?
|
| Arthritis, Reactive | 1 | 1982 | 1 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2022 | 3 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 10 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2022 | 6 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2022 | 48 | 0.050 |
Why?
|
| Thrombosis | 1 | 2022 | 14 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2022 | 32 | 0.050 |
Why?
|
| Alberta | 1 | 2021 | 4 | 0.050 |
Why?
|
| Internet | 1 | 2023 | 207 | 0.040 |
Why?
|
| Carrier State | 1 | 2021 | 8 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2021 | 9 | 0.040 |
Why?
|
| Sacrococcygeal Region | 1 | 2001 | 1 | 0.040 |
Why?
|
| Diskectomy | 1 | 2001 | 1 | 0.040 |
Why?
|
| Prednisolone | 1 | 2001 | 4 | 0.040 |
Why?
|
| Sciatica | 1 | 2001 | 2 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 2001 | 3 | 0.040 |
Why?
|
| Animals | 1 | 2021 | 285 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2021 | 1161 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2001 | 16 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 84 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2021 | 129 | 0.040 |
Why?
|
| Fibromyalgia | 1 | 1998 | 4 | 0.040 |
Why?
|
| Patient Comfort | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cryotherapy | 1 | 2018 | 4 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 1998 | 36 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 35 | 0.030 |
Why?
|
| Nails, Malformed | 1 | 1997 | 2 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1295 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 58 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1997 | 22 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 214 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 268 | 0.030 |
Why?
|
| Child Abuse | 1 | 2018 | 45 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2019 | 256 | 0.030 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2017 | 96 | 0.030 |
Why?
|
| Motivational Interviewing | 1 | 2017 | 36 | 0.030 |
Why?
|
| Synovial Membrane | 1 | 1996 | 1 | 0.030 |
Why?
|
| Pharmacoepidemiology | 1 | 2015 | 18 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 85 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 308 | 0.030 |
Why?
|
| Prevalence | 1 | 2015 | 830 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 486 | 0.020 |
Why?
|
| Ohio | 1 | 2011 | 23 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 84 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 116 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 90 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 204 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2011 | 119 | 0.020 |
Why?
|
| Disease Notification | 1 | 2007 | 6 | 0.020 |
Why?
|
| Health Resources | 1 | 2007 | 39 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 51 | 0.020 |
Why?
|
| Hospitals | 1 | 2007 | 71 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 234 | 0.020 |
Why?
|
| Endocarditis | 1 | 1982 | 1 | 0.010 |
Why?
|
| Yersinia enterocolitica | 1 | 1982 | 1 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1982 | 30 | 0.010 |
Why?
|
| Epidural Space | 1 | 2001 | 2 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2001 | 3 | 0.010 |
Why?
|
| Injections, Epidural | 1 | 2001 | 6 | 0.010 |
Why?
|
| Fibrosis | 1 | 2001 | 6 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2001 | 144 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 1998 | 34 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1996 | 1 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1996 | 1 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1996 | 2 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 3 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 18 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 17 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1996 | 25 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1996 | 302 | 0.010 |
Why?
|
Concepts
(248)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->